Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UMPS | P11172 | 1/20 | 0.44 |
| ▸ | PYGL | P06737 | 7/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | PNP | P00491 | 2/20 | 0.36 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4557441 | 0.87 | UMPS (0.52) | UMPSPYGLPAX8PNP | |
| SCHEMBL21539496 | 0.87 | UMPS (0.52) | UMPSPYGLPAX8PNP | |
| SCHEMBL9053021 | 0.78 | UMPS (0.48) | UMPSPYGLPNP | |
| SCHEMBL15820221 | 0.78 | UMPS (0.47) | UMPSPYGLSLC5A2 | |
| SCHEMBL5795431 | 0.69 | UMPS (0.54) | UMPSPYGLPNP | |
| SCHEMBL22235673 | 0.69 | UMPS (0.54) | UMPSPYGLPNP | |
| Pyrazofurin SCHEMBL21379808 | 0.69 | UMPS (0.61) | UMPSPYGLPNP | |
| SCHEMBL21539497 | 0.69 | PYGL (0.61) | UMPSPYGL | |
| Pyrazofurin SCHEMBL28176565 | 0.69 | UMPS (0.60) | UMPSPYGLPNP | |
| Pyrazofurin SCHEMBL28138546 | 0.68 | UMPS (0.58) | UMPSPYGLPNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014696-A1 | Specificity in treatment of diseases | VALEANT RESEARCH & DEVELOPMENT | 2004-01-22 | — | — | US | disclosed |
| EP-1351966-A1 | IMPROVED SPECIFICITY IN TREATMENT OF DISEASES | Ribapharm Corp (US) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002016382-A1 | IMPROVED SPECIFICITY IN TREATMENT OF DISEASES | RIBAPHARM INC. (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014696-A1 | Specificity in treatment of diseases | GLS2, GOT2, SHMT2 | UMPS 715/4885PYGL 19/4885PAX8 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.